What is the current status of Retatrutide?
19 dated records across 3 evidence lanes in the selected collection.
Read the cited answer →Public beta · Selective source coverage
Peptide records.
Without the hype.
Look up a peptide across selected U.S. label, trial, PubMed metadata, and regulator records, see what connects to it, and open the original sources. Coverage is selective and not continuous.
- This page shows
- Selected public records connected to a peptide, with links to the original sources.
- It does not establish
- Record inclusion is not a treatment rating, endorsement, or medical advice.
Browse all 2625 dated updates and inspect the site's 2664 cited official records. Inclusion is coverage—not endorsement—and the current source set is not comprehensive. Open the dated archive or see exact coverage and gaps.
Start with a direct answer
Living peptide status briefs
These canonical profiles lead with the status supported by their cited records, then separate trials, literature metadata, regulatory context, recent additions, and explicit unknowns.
What is the current status of BPC-157?
50 dated records across 3 evidence lanes in the selected collection.
Read the cited answer →What is the current status of GHK-Cu?
16 dated records across 1 evidence lane in the selected collection.
Read the cited answer →Regulatory trackerFDA peptide compounding statusAdvisory review, compounding categories, and approval kept distinct.Weekly briefingSource changes versus historical additionsTwo timelines, clearly labeled.Public change ledgerWhat changed recently?Additions, profile revisions, corrections, and retractions with preserved before-and-after evidence.
Explore by evidence depth
Start with the most connected research hubs.
These profiles connect the largest number of dated records in PeptideScanner’s current collection. Counts describe selected source coverage—not research quality, importance, safety, or effectiveness.
299dated records
Glucagon
- Evidence types
- 4
- Cited sources
- 299
- Source years
- 23
1960–2026 in the selected record set
232dated records
Semaglutide
- Evidence types
- 4
- Cited sources
- 232
- Source years
- 10
2017–2026 in the selected record set
212dated records
Leuprolide
- Evidence types
- 4
- Cited sources
- 212
- Source years
- 32
1985–2026 in the selected record set
165dated records
Tirzepatide
- Evidence types
- 4
- Cited sources
- 165
- Source years
- 5
2022–2026 in the selected record set
164dated records
Liraglutide
- Evidence types
- 4
- Cited sources
- 164
- Source years
- 17
2009–2026 in the selected record set
157dated records
Octreotide
- Evidence types
- 4
- Cited sources
- 157
- Source years
- 25
1988–2026 in the selected record set
How to use PeptideScanner
Start with the record, then inspect the evidence.
Find a profile
Search a peptide name or source-mapped related name, or browse by status and topic.
Read what is supported
Profiles separate current source-backed statements from medical advice, recommendations, and unsupported conclusions.
Open the sources
Follow the citations to the exact public records and review any dated updates connected to the profile.
Discover
Start with peptide profiles
UnapprovedUnapproved and safety records
BPC-157
Related names: Body protection compound 157
A research peptide represented by FDA compounding-review material and one selected trial-registry record.
Open profile →InvestigationalMetabolic
Cagrilintide
Related names: AM833
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
Open profile →Safety review recordSafety records
GHK-Cu
Related names: Copper tripeptide-1, GHK copper
A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.
Open profile →UnapprovedUnapproved and safety records
Ipamorelin
Related names: Ipamorelin acetate
A peptide named in FDA compounding-risk and DOJ enforcement records.
Open profile →InvestigationalMetabolic
Retatrutide
Related names: LY3437943
A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
Open profile →U.S. label recordMetabolic
Semaglutide
Related names: Wegovy, Ozempic
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
Open profile →InvestigationalMetabolic
Survodutide
Related names: BI 456906
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
Open profile →U.S. label recordMetabolic
Tirzepatide
Related names: Zepbound, Mounjaro
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
Open profile →Fresh from the sources
Latest peptide research
Regulatory · Exenatide
Federal Register notice 2026-16998
The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
Source: Federal Register via GovInfo ↗
Regulatory · Abaloparatide
Abaloparatide DailyMed SPL version 19
DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Semaglutide
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Glucagon
Geographic Disparities in Glucagon Prescriptions Across North Carolina.
PubMed lists PMID 40513916 in American journal of preventive medicine as Journal Article, with publication-date metadata of 2025-06-11 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Liraglutide
Treatment of obesity with liraglutide in bipolar disorder: a case report.
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Browse by topic
Find a clearer starting point.
Our standard
“Report what the source says—then show the source.”
PeptideScanner separates regulatory records, trial registrations, and company or institutional statements from established scientific truth. If something is unclear, we label the uncertainty or leave it unpublished.
Read our methodology